RIBI stumbles in transition to Phase III

RIBI stumbles in transition to Phase III Ribi ImmunoChem Research Inc. (RIBI) has provided another example of the difficulty of replicating Phase II trial results when the patient population is changed for Phase III.

Phase II trials of RIBI's Melacine melanoma therapeutic vaccine had shown a median survival of 20 months compared to historical data showing 9 to 12 month survival after chemotherapy. However, those trials had enrolled a mixed range of patients with different stages of the disease. ...